



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

MJ

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/526,543	09/07/2005	Kazuhiko Imakawa	2005_0329A	5184
513	7590	05/31/2007	EXAMINER	
WENDEROTH, LIND & PONACK, L.L.P.			KEMMERER, ELIZABETH	
2033 K STREET N. W.			ART UNIT	PAPER NUMBER
SUITE 800			1646	
WASHINGTON, DC 20006-1021			MAIL DATE	DELIVERY MODE
			05/31/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/526,543	IMAKAWA ET AL.
	Examiner	Art Unit
	Elizabeth C. Kemmerer, Ph.D.	1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 07 September 2005.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-31 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-31 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 2, 4, 9 (in part), 10 (in part), and 11 (in part), drawn to pharmaceutical compositions comprising IP-10 polypeptides.

Group II, claim(s) 3, drawn to methods of administering IP-10 polypeptide to a patient or sample.

Group III, claim(s) 10 (in part), 11 (in part), 13 (in part), 14 (in part), 18, 19, and 20, drawn to IP-10 polynucleotides and oligonucleotides.

Group IV, claim(s) 5, 10 (in part), and 11 (in part), drawn to methods of measuring IP-10 polypeptide activity in a sample, including diagnostic methods, said methods using IP-10 polypeptide.

Group V, claim(s) 6, drawn to a structurally undefined reagent useful in an assay for measuring an IP-10 activity.

Group VI, claim(s) 7, 8, and 9 (in part), drawn to gene therapy reagents and methods.

Group VII, claim(s) 10 (in part), 11 (in part), 15, 16, 24, 25, and 27, drawn to screening or diagnostic methods using IP-10 polynucleotides.

Group VIII, claim(s) 12, drawn to a structurally undefined compound for controlling the production of IP-10.

Group IX, claim(s) 13 (in part) and 14 (in part), drawn to restriction enzymes.

Group X, claim(s) 21, 22, 29, and 31, drawn to IP-10 antibodies and kits comprising the same.

Group XI, claim(s) 23, 26, 28, and 30, drawn to methods of measuring IP-10 with an IP-10 antibody.

The inventions listed as Groups I-XI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The PCT rules define a special technical feature as a feature which distinguishes a claimed invention over the prior art. However, the first claimed invention is not distinguished over the prior art. For example, US 5,824,299 (Luster et al., issued 20 October 1998) teaches a pharmaceutical composition or drug comprising an effective amount of IP-10 protein that expressly has the activity of activating immunocyte (T cell) migration, and inherently has the other biological activities recited in claim 1. See col. 1, li. 18; col. 11-12, section V. Thus, since the first claimed invention does not have a special technical feature, it cannot share a special technical feature with the other inventions listed above. Furthermore, a significant search burden would be imposed on the office if the inventions were examined together. For example, search of the protein, nucleic acid and antibody each involve a non-overlapping search of the sequence and literature databases. Prior art disclosing an isolated IP-10 polypeptide may not provide any structural information on the encoding polynucleotide or various oligomers and primers with the activities recited in the claims. Additionally, all of the method claims require different reagents, patients, and methodology, all of which would have to be searched and considered during examination.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth C. Kemmerer, Ph.D. whose telephone number is (571) 272-0874. The examiner can normally be reached on Monday through Thursday, 7:00 a.m. to 5:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, Ph.D. can be reached on (571) 272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ECK



ELIZABETH C. KEMMERER, PH.D.
PRIMARY EXAMINER